AZP 3813
Alternative Names: AZP-3813Latest Information Update: 18 Jul 2024
At a glance
- Originator PeptiDream
- Developer Amolyt Pharma
- Class Macrocyclic compounds; Peptides
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Acromegaly
Most Recent Events
- 15 Jul 2024 Amolyt Pharma has been acquired by AstraZeneca
- 15 Jun 2023 Updated pharmacodynamics data from a preclinical study in acromegaly presented at the 105th Annual Meeting of the Endocrine Society (ENDO-2023)
- 05 Jun 2023 Phase-I clinical trials in Acromegaly (In volunteers) (unspecified route)